CaptureSelect™ IgA-XL Affinity Matrix

CaptureSelect IgA-XL Affinity Matrix is intended for the purification of human IgA, with no binding to other immunoglobulins. The IgA-XL affinity matrix provides improved binding capacities (>15 g/L IgA) and elution characteristics (full elution at pH 4) compared to CaptureSelect IgA Affinity Matrix.

Features of this affinity matrix include:

• Purification of all IgA serotypes: IgA1, IgA2, dimeric IgA, and S-IgA (secretory IgA)
• IgA purification from plasma, serum, and recombinant sources
• Efficient purification of IgA with high yields and retained activity
• Excellent scalability
• Non-animal-derived

CaptureSelect IgA-XL Affinity Matrix binds to the Fc part of IgA. The high selectivity and yields obtained using IgA-XL Affinity Matrix enable a robust, fast, and efficient purification process with excellent purity obtained in one step.

Animal origin statement

CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12–15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (animal origin-free).

Main characteristics

• Matrix: agarose-based, epoxide activated
• Average particle size: 65 ± 10 μm
• Ligand: CaptureSelect IgA-XL affinity ligand
• Ligand coupling method: epoxide
• Binding capacity: > 15 g/L at 5 minutes residence time, tested with plasma-derived polyclonal IgA
• Elution conditions: 20 mM sodium citrate, pH 4
• Flow characteristics: 50–200 cm/h (up to 2 bar)
• Formulation buffer: 20% (v/v) ethanol